ATP III GP, Ltd. 4
4 · Akero Therapeutics, Inc. · Filed Jun 25, 2019
Insider Transaction Report
Form 4
Apple Tree Partners IV, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-06-24+4,228,764→ 4,228,764 total - Conversion
Common Stock
2019-06-24+286,439→ 4,515,203 total - Purchase
Common Stock
2019-06-24$16.00/sh+900,000$14,400,000→ 5,415,203 total - Conversion
Series A Preferred Stock
2019-06-24−13,000,000→ 0 total→ Common Stock (4,228,764 underlying) - Conversion
Series B Preferred Stock
2019-06-24−880,568→ 0 total→ Common Stock (286,439 underlying)
Footnotes (5)
- [F1]Represents the total number of shares of common stock received by Apple Tree Partners IV, L.P. ("ATP") upon the conversion of the Issuer's Series A Preferred Stock in connection with the closing of the Issuer's initial public offering.
- [F2]All series of preferred stock automatically converted into the Issuer's common stock on a 3.07418-for-one basis upon the closing of the Issuer's initial public offering on June 24, 2019 and had no expiration date.
- [F3]Represents the total number of shares of common stock received by ATP upon the conversion of the Issuer's Series B Preferred Stock in connection with the closing of the Issuer's initial public offering.
- [F4]These shares are owned directly by ATP. ATP III GP, Ltd.("ATP GP") is the sole general partner of ATP. Seth L. Harrison is a director on the Issuer's board of directors and is the sole director of ATP GP. ATP GP disclaims beneficial ownership of the shares listed, except to the extent of its pecuniary interest therein.
- [F5]On June 24, 2019, ATP purchased 900,000 shares of common stock of the Issuer at a price of $16.00 per share pursuant to an underwritten public offering.